CRISPR/Cas9‐mediated genome editing: from basic research to translational medicine by Jacinto, Filipe et al.
J Cell Mol Med. 2020;00:1–13.    |  1wileyonlinelibrary.com/journal/jcmm
1  | INTRODUC TION
Genome editing is a type of genetic engineering where DNA is ma-
nipulated at the single-base level. It is revolutionizing the biomedical 
research field and holds promise to treat or prevent many human 
genetic disorders. The perfect genome-editing tool has to be able 
to alter a genomic sequence efficiently, showing high DNA se-
quence specificity, and minimal off-target effects.1 Genome-editing 
strategies were first developed in yeast 2,3 and then in mammalian 
cells,4,5 in which small portions of the genome were substituted 
with exogenous donor DNA sequences via the endogenous homol-
ogous recombination repair pathway. In the late 80s, this same nat-
ural homologous recombination-based approach was used in mouse 
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Abstract
The recent development of the CRISPR/Cas9 system as an efficient and accessi-
ble programmable genome-editing tool has revolutionized basic science research. 
CRISPR/Cas9 system-based technologies have armed researchers with new power-
ful tools to unveil the impact of genetics on disease development by enabling the 
creation of precise cellular and animal models of human diseases. The therapeutic 
potential of these technologies is tremendous, particularly in gene therapy, in which 
a patient-specific mutation is genetically corrected in order to treat human dis-
eases that are untreatable with conventional therapies. However, the translation of 
CRISPR/Cas9 into the clinics will be challenging, since we still need to improve the 
efficiency, specificity and delivery of this technology. In this review, we focus on 
several in vitro, in vivo and ex vivo applications of the CRISPR/Cas9 system in human 
disease-focused research, explore the potential of this technology in translational 
medicine and discuss some of the major challenges for its future use in patients.
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embryonic stem cells to generate mice with a specific genotype.6 
Since then, this technique has enabled the study of human diseases 
in mouse and other animal models and contributed considerably in 
the process of drug discovery and development.
Nevertheless, this approach has several limitations, such as its 
low editing efficiency and unwanted genome-editing events where 
the donor DNA template is more frequently inserted into the ge-
nome randomly than at the desired location.7 To overcome these 
limitations, several groups have developed tools that allowed the 
introduction of site-specific double-stranded breaks (DSBs) into a 
genomic locus of interest using ‘meganucleases’. This refers to en-
donucleases with an extremely rare recognition site that recognizes 
and cleaves specific DNA sequences in order to stimulate homolo-
gy-directed repair (HDR) mechanism.8-11 This approach requires that 
a DNA donor template with ends homologous to the break site is 
delivered and used by the polymerase to copy information along the 
break site.9,10 However, besides HDR, non-homologous end joining 
(NHEJ) also occurs at the sites of DSBs.11 NHEJ is able to unify the 
two ends of the break by introducing a random nucleotide insertion 
or deletion (indels). While NHEJ repair mechanism is exceptionally 
successful in obtaining functional gene knockouts, the generation of 
indels emerges as an undesired side effect.12 Therefore, the gener-
ation of site-specific DSBs that specifically trigger HDR and simul-
taneously blunt NHEJ activity is still a current challenge in the field.
Alternatively, site-directed zinc finger nucleases (ZFs)13-15 and 
transcription-activator-like effector nucleases (TALENs)16,17 are 
two approaches that use the principles of DNA-protein recognition. 
Both ZFs and TALENs are fusion proteins made up of an engineered 
DNA binding domain fused to a non-specific nuclease domain from 
the FokI restriction enzyme. Unlike DNA-binding proteins, ZF and 
TALEN amino acid sequences can be designed to cleave virtually any 
target sequence in the genome with high specificity.17-22 However, 
the routine use of these editing tools in the laboratory has been im-
paired by difficulties in protein design, synthesis and validation.23
The development of the CRISPR/Cas9 system has proven to be a 
major scientific breakthrough and made gene editing more accessible. 
Distinct from the protein-guided DNA cleavage used by TALENs and 
ZFs, CRISPR/Cas9 depends on a small RNA to introduce a site-spe-
cific DSB.24-26 The requirements of the endonuclease Cas9 to match a 
DNA target sequence are elegant and simple: It only requires a 20-nu-
cleotide ‘guideRNA’ (sgRNA) that base pairs with the target DNA and 
the presence of a DNA ‘protospacer-adjacent motif’ (PAM), a short 
DNA sequence adjacent to the complementary region that varies ac-
cording to the bacterial species of the Cas9 protein being used.23-29 
This two-pronged system in which the sgRNA guides the Cas9 nucle-
ase to target any DNA sequence of interest has replaced the laborious 
protein design procedure associated with ZFs and TALENs.1,24-26
The simplicity of CRISPR/Cas9 technology coupled with a 
unique DNA cleaving mechanism, the ability to target multiple re-
gions, and the existence of different type II CRISPR-Cas system 
variants, has enabled notable progresses using this cost-effective 
and user-friendly technology to precise and efficiently modify the 
genomic DNA of a wide collection of cells and organisms.23 Although 
the CRISPR/Cas9 system has been widely adopted as the preferred 
genetic editing tool for most researches worldwide, the use of this 
technology in pre-clinical and clinical setting is now bursting with 
new and exciting studies. In this review, we summarize some of the 
recent disease-focused studies that have applied the CRISPR/Cas9 
system and explore the advantages of this technology as well as dis-
cuss the major obstacles involved in translating it to the clinic.
2  | CRISPR /C A S9:  HISTORY AND 
MECHANISM
In 1987, Ishino et al.30 noticed in Escherichia coli, the presence of a 
cluster of repetitive DNA sequences separated by variable spacer 
regions. Later, Mojica et al identified identical type of repeated 
sequences in numerous bacteria and archaea and named them 
Clustered Regularly Interspaced Palindromic Repeats or CRISPR.31 
Interestingly, the biggest breakthrough came in 2005 when the same 
group realized that these spacer sequences were from unknown ori-
gin.32-34 Together with the observation that many CRISPR-associated 
(Cas) genes encode proteins with putative nuclease and helicase do-
mains, it was postulated that CRISPR may constitute an adaptive 
immunity system 33-36 by using RNAs as memory signatures of previ-
ous infections.37 In 2007, Barrangou et al.38, using a well-character-
ized phage-sensitive S thermophilus strain and two bacteriophages, 
showed experimentally that CRISPR confers adaptive immunity. In 
2008, CRISPR RNAs (crRNAs) were shown to serve as guides in a 
complex with Cas proteins to promote phage resistance.39 The same 
year, Marraffini and Sontheimer recognized that CRISPR/Cas sys-
tem was essentially a programmable restriction enzyme targeting 
DNA.40 Interestingly, their paper was the first to explicitly predict 
that CRISPR might be repurposed for genome editing in heterolo-
gous systems. In recent years, work from different groups has been 
crucial to identify the different components that constitute the re-
combinant CRISPR/Cas9 system and immense work has been done 
to demonstrate its functionality in mammalian cells.1,23,25,27,41,42
CRISPR mechanisms are very diverse but can be mainly classified 
into two distinct classes, class 1 and class 2, depending on the orga-
nization of the effector protein complex. Class 1 comprehend three 
different types I, III and IV that are further subdivided into 15 sub-
types. Distinct from class 1, that is characterized by the presence of 
a multi-protein effector complex, class 2 is defined by a single-pro-
tein effector module. This class is divided into types II, V and VI.43 
The other CRISPR systems have been extensively reviewed else-
where.44,45 In CRISPR type II, DNA from viruses or plasmids of pre-
vious infections is cut into small pieces and integrated into a CRISPR 
locus amongst short repetitive sequences (30-40 bp) separated by 
equally short spacer sequences. The loci are transcribed, and pre-
cursor CRISPR RNAs (pre-crRNAs) are then processed to generate 
small crRNAs. The pre-crRNA processing relies on a trans-activating 
CRISPR RNA (tracrRNA) that has sequence complementarity to the 
CRISPR repeat sequence. Upon crRNA:tracrRNA base pairing, which 
is stabilized by Cas9, endogenous RNAse III cleaves the precursor 
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RNA (pre-crRNA) into mature crRNAs. The latter are used as guide 
sequences that will lead Cas nucleases to target and cleave invading 
DNA based on sequence complementarity. Cleavage of the target 
sequence, also known as a protospacer, triggers a host immune re-
sponse by destroying the invader's genome.23-27,29,46 The character-
istic that makes the type II CRISPR mechanism unique compared to 
other CRISPR systems is the fact that only one Cas protein (Cas9) 
is required for gene silencing.23,27 During the destruction of target 
DNA, the two nuclease domains of Cas9, the HNH and RuvC-like 
nuclease domains, cleave both DNA strands matching the 20-nucle-
otide target sequence resulting in the formation of double-stranded 
breaks (DSBs).25,47 The HNH domain and the RuvC domains cleave 
the complementary strand and non-complementary strand, respec-
tively.47 The Cas9 double-stranded endonuclease activity also re-
quires that a short-conserved sequence (2-5 nucleotides), known 
as protospacer adjacent motif (PAM), is present immediately down-
stream of the 3´ crRNA. DNA is cleaved three base pairs upstream 
of the PAM sequence in the complementary DNA strand. In fact, 
the activity of Cas9 is impaired in the absence of a PAM sequence 
even if there is complete complementarity by the Cas9-RNA.48 It is 
important to note that the Cas9 can cleave the non-complementary 
DNA strand and generate DSB within 3 bp to 8 bp upstream of the 
PAM.25 This can be of relevance when aiming to perform precise 
gene editing in a therapeutic setting.
The natural occurring type II CRISPR mechanism is a simple 
three-component system (Cas9 along with the crRNA and tracRNA) 
that showed promising potential to be adapted for genome editing. 
A major milestone came in 2012 when Doudna and Charpentier 
laboratories developed a simplified two-component CRISPR/Cas9 
system by combining tracRNA and crRNA into a single guide RNA 
(sgRNA).25 This combined version is shown to be as effective as Cas9 
programmed with separate tracRNA and crRNA in guiding targeted 
gene alterations (Figure 1).25 The CRISPR/Cas9 system is the most 
simple, effective and versatile system to date, requiring only the de-
sign of a customized sgRNA to generate DSBs at almost any DNA 
target site. For this reason, this editing technology has quickly wide-
spread within the scientific community to manipulate the genome of 
numerous cell types and organisms ranging from mice and monkeys 
to primary human T cells, organoid cultures and stem cells, as well as 
plants, bacteria and fungi.49
3  | CRISPR /C A S9:  AN EFFICIENT TOOL 
FOR GENOME EDITING IN MAMMALIAN 
CELL S
3.1 | In vitro applications
3.1.1 | The first studies: a proof of concept
In January 2013, three independent studies have shown that CRISPR/
Cas9 mechanism could be repurposed to generate DSBs in DNA. By 
tweaking this naturally occurring mechanism, researchers were able 
to perform mammalian genome editing using DNA repair systems, 
including the NHEJ and the less-frequent template HDR.25,42 NHEJ 
is the preferred pathway to generate gene knockouts by inducing in-
dels within a coding exon, which might ultimately lead to frameshift 
mutations and premature stop codons. Alternatively, HDR is used 
to introduce or alter a specific sequence by using properly designed 
repair templates (Figure 1A).25,42 Cong et al.42 developed a more 
precise variant of the CRISPR/Cas9 system by generating a mutant 
form that only has nickase activity, known as Cas9D10A or Cas9n. 
Cas9D10A cuts DNA to generate single-stranded breaks and does 
not activate NHEJ. Instead, the HDR repair pathway is activated in 
the presence of a homologous repair template resulting in reduced 
indel mutations (Figure 1B). Since 2013, numerous studies have 
demonstrated the efficacy of this technology by successfully editing 
the genome of a wide range of cells and organisms.49
3.1.2 | Application of the CRISPR/Cas9 system in 
cancer biology
The cancer genetics field is one of the research areas in which 
CRISPR is having a significant impact. With CRISPR, it is now pos-
sible to quickly induce loss-of-function (LOF) and gain-of-function 
(GOF) mutations in tumour suppressor genes, oncogenes or other 
relevant players of the malignant transformation process.50 For 
example, a study by Matano et al. have demonstrated how CRISPR 
could be used to improve our understanding of human colorectal 
cancer (CRC) development and progression by introducing serial 
LOF and GOF mutations frequently associated with CRC in un-
transformed human intestinal organoids. Surprisingly, the authors 
found that they could not entirely recapitulate the tumorigenic 
and metastatic characteristics of this human disease, suggesting 
that additional genetic and/or epigenetic events are required for 
the invasive behaviour of CRC.51 The CRISPR/Cas9 system is also 
an invaluable tool to introduce chromosomal translocations that 
mimic those described in cancers such as lung cancer, acute my-
eloid leukaemia or Ewing sarcoma.52-55 Human cancer cell lines 
harbouring these translocations can be obtained by triggering two 
distant DSBs at defined positions. In addition, the ability to use 
CRISPR/Cas9 in large-scale functional screenings offers the op-
portunity to identify essential genes in various cancer cell lines, 
uncover genes that are involved in the response to small-molecule 
inhibitors or confer resistance to multiple compounds, dissect the 
relative importance of viral host factors and study combinatorial 
vulnerabilities.56-59 Most of the CRISPR/Cas9 screens use pooled 
lentiviral libraries to deliver sgRNAs into the cells. To guarantee 
high confidence on hit identification, the majority of screens in-
clude 3 to 10 sgRNAs per gene.60 Remarkable advances using 
CRISPR/Cas9 technology have been made in cancer immunother-
apy. Patient autologous T cells can be genetically edited in vitro 
to express chimeric antigen receptors (CARs) that specifically rec-
ognize and kill tumour cells. These genetically engineered T cells 
expressing tumour-targeting receptors have shown therapeutic 
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potential in clinical trials for the treatment of various leukaemias 
and lymphomas and may eventually be successful in treating solid 
tumours.61 CD19, an antigen expressed by normal B cells and re-
lated malignancies, was one of the first targets for CAR T cell–
mediated immunotherapy. Currently, different clinical trials are 
evaluating CAR T therapies targeting antigens in solid tumours, 
such as Her2/neu, Mesothelin cMet, GD2, interleukin-13 receptor 
alpha 2 (IL13Rα2), CEA and EGFR.60,62
3.1.3 | Application of the CRISPR/Cas9 system 
in patient-derived primary and induced pluripotent 
stem cells
Since the discovery by Yamanaka and colleagues that somatic 
cells could be reprogrammed into a pluripotent state, human in-
duced pluripotent stem cells (iPSCs) have held great promise in 
several disease models, regenerative medicine, drug discovery and 
F I G U R E  1   CRISPR/Cas9 genome-editing tools in mammalian cells. (A) Double-stranded DNA breaks (DSBs) are generated by CRISPR/
Cas9 system, which triggers endogenous DNA repair mechanisms resulting in genetic manipulation. Non-homologous end joining (NHEJ) 
is an error-prone mechanism that is able to disrupt the target gene through the formation of insertions/deletions (indels). Alternatively, 
homology-directed repair (HDR) could be activated in the presence of a properly designed DNA repair template to alter a DNA sequence at 
a specific locus. (B) Mutated Cas9 with only nickase activity (Cas9n) makes a site-specific single-stranded nick and does not activate NHEJ. 
Double-stranded breaks only occur upon delivery of two sgRNAs that can be later repaired by HDR or NHEJ. (C) Nuclease-deficient Cas9 
(dCas9) can be fused to different effector domains, which allow for the activation or repression of particular target genes in their native 
context without creating DSBs
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development.63,64 Because CRISPR has shown to be highly efficient 
at genome editing in iPSCs when compared to alternative systems 
like TALENs or ZFs, this technology has been commonly used to gen-
erate iPSC-based models of human disease.65,66
There are different approaches to generate isogenic disease mod-
els in iPSCs using the CRISPR/Cas9 system. For example, it is possi-
ble to generate Cas9-mediated iPSC knockout cell lines via NHEJ that 
could be used to determine whether a given human mutation is indeed 
directly responsible for causing the disease or to simply study gene 
function.67-70 As an alternative approach, specific disease-related mu-
tations could be introduced into iPSCs using the CRISPR/Cas9 system 
and HDR-mediated genome editing to generate in vitro models of 
human disease.67,71 A study by Wang et al.72 have demonstrated how 
CRISPR could be used to help researchers around the world to decipher 
the underlying cause of human genetic diseases. In this study, the au-
thors shed new light on the pathophysiology underlying the cardiomy-
opathy of Barth syndrome (BTHS), a mitochondrial disorder caused by 
a mutation on the tafazzin (TAZ) gene, by combining tissue engineering 
with patient-derived and genetically engineered iPSCs.72 Furthermore, 
the authors were able to assess the effect of potential therapies for 
Barth syndrome using these BTHS iPSC-derived cardiomyocytes. This 
pioneering study lays groundwork to develop ‘patient-to-patient’ treat-
ment strategies.72 Finally, as iPSCs have the capacity to differentiate 
into any cell type, the generation of genetically engineered iPSCs al-
lows the proper study of human genetic variations in a broad array of 
tissues in cell culture.1
One of the most exciting CRISPR/Cas9 applications with relevance 
to human health is gene therapy, in which a patient-specific mutation 
or mutations are genetically manipulated in order to provide a defin-
itive cure.1 Different groups have used in their studies, the CRISPR/
Cas9 system to correct human genetic mutations in patient-derived 
primary cells, including Fanconi anaemia,73 Duchenne muscular dystro-
phy (DMD),74 haemophilia,75 cystic fibrosis76 and beta thalassaemia.77 
Additionally, primary immune cells have been edited to knockout the 
CCR5 or CXCR4 receptor genes using CRISPR/Cas9, resulting in cells 
resistant to HIV infection.1,78-80 Together, all these studies highlight the 
impact that this technology might have in the forthcoming future for 
the treatment of human genetic disorders.
3.1.4 | Application of the CRISPR/Cas9 system in 
transcriptional regulation
Besides enabling the edition of mammalian genomes, researchers 
have now the possibility of regulating gene expression and altering 
epigenetic states. Alterations to the CRISPR/Cas9 system facilitated 
this new feature without introducing DSBs,81 thereby avoiding un-
desired permanent mutations in target genomic loci. By fusing the 
viral transcriptional activation domain VP64 to a nuclease-deficient 
Cas9 (dCas9), it has been possible to induce the expression of a wide 
range of genes within their native chromosomal context.82,83 This 
Cas9 version is referred to as CRISPR/Cas9 activation or CRISPRa. 
However, in the majority of the cases the dCas9-VP64 system 
required multiple sgRNAs complementary to the target sequence to 
achieve strong gene activation.82,84 A strategy to boost gene expres-
sion levels was to couple several transcriptional activation domains 
to the dCas9/sgRNA complex (eg tripartite activator system [dCas9-
VPR], synergistic activation mediator [SAM] or dCas9-SunTag).85-87 
These second-generation dCas9-activator fusions proved to ex-
hibit robust transcriptional activation in wide panel of mammalian 
cell types (Figure 1C).88 Furthermore, CRISPRa can be used in ge-
netic screens to unveil molecular targets of novel compounds or to 
study drug resistance mechanisms in cancer cells. Yang et al.89 used 
a genome-scale CRISPRa screen and identified Sall1 as a gene that 
contributes to reprogramming mouse embryonic fibroblasts into in-
duced pluripotent stem cells.
Conversely, dCas9 has also been utilized in genome-wide exper-
iments for targeted gene transcriptional repression.1,23 Commonly 
known as CRISPR interference (CRISPRi), this strategy relies on the 
fact that dCas9 shows high affinity to target DNA and therefore 
can be repurposed as a transcriptional repressor by blocking tran-
scriptional elongation, RNA polymerase binding and recruitment of 
transcription repressors.81 Moreover, dCas9 can also be fused to the 
Kruppel-associated box (KRAB) transcriptional repressor for effi-
cient target gene silencing (Figure 1C).82,90,91
Overall, these dCas9 versions that allow for the activation 
(CRISPRa) or repression (CRISPRi) of target genes are powerful tools 
that can be used for functional genomic studies under different 
physiological and developmental conditions without creating DSBs. 
More recently, an in vivo study on a type I diabetes mouse model 
repurposed Cas9 to epigenetically induce gene activation and ob-
served a significant improvement on disease phenotypes such as 
acute kidney injury and muscular dystrophy.92 This study further 
supports that a Cas9-mediated epigenetic remodelling of target loci 
could potentially be used as a powerful therapeutic tool to treat sev-
eral human diseases.
3.2 | In vivo applications
3.2.1 | Application of the CRISPR/Cas9 system 
in the rapid generation of animal models
CRISPR/Cas9 technology brought a lot of excitement within the sci-
entific community since it revolutionized how fast researchers are 
able to make a genetically modified animal models.60 Previously, 
the generation of a mouse model was a time-consuming process 
that comprehended several laborious steps. Initially, an embry-
onic stem cell had to be edited to introduce the desired mutation 
and then injected into the mouse blastocyst. Finally, the offspring 
had to be screened for germline transmission.93 This process was 
inefficient, labour-intensive and expensive, which has slowed the 
generation of genetically engineered animal models. In 2013, the 
CRISPR/Cas9 system was adapted as an efficient gene-targeting 
technology to generate mice carrying mutations in multiple genes 
in a single editing step by zygote injection.94 A few months later, the 
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same group used the CRISPR/Cas9 system to develop a one-step 
knock-in procedure to generate mice carrying reporter and condi-
tional alleles.95 Since then, several studies have shown that injecting 
CRISPR/Cas9 components (Cas9 messenger RNA or protein; sgRNA; 
HDR template) into a zygote can lead to efficient gene knockout at 
multiple loci in several animal species, including mice,96,97 rat,97,98 
rabbits99 and monkeys,100 bypassing targeting in embryonic stem 
cells. Moreover, the microinjection of zygotes with CRISPR/Cas9 
enables researchers to generate additional mutations in pre-existing 
animal models of diseases without the need for embryonic stem cell 
derivation or complex genetic crosses.60 Finally, being that CRISPR/
Cas9 is a novel genome-engineering technology that facilitates 
multiplexed gene targeting, multiple genes can be targeted simul-
taneously. Therefore, it is easy to obtain mice with multiple gene 
knockout without the need for crossing single knockout strains.60 
This is of great interest when the goal is to generate animal models 
for complex diseases such as cancer. It is important to bear in mind 
that the majority of the published studies have been performed in 
murine cancer models that only harbour a low number of mutated 
genes or alleles.101,102 Therefore, the CRISPR/Cas9 system provides 
an alternative to study cancer in models that resemble the genetic 
heterogeneity of human cancer genomes. It facilitates the genera-
tion of genetically engineered mouse models that harbour mutations 
in multiple genes involved in cancer progression and also allows the 
induction of chromosomal translocations or other chromosomal re-
arrangements, characteristic of many human cancers.50 Altogether, 
CRISPR/Cas9 promises to revolutionize the generation of geneti-
cally modified animal models of disease for translational applications 
by reducing the cost and the time that is necessary to generate in 
vivo targeted models.
3.2.2 | Application of the CRISPR/Cas9 system in 
animal models for the treatment of human diseases
CRISPR/Cas9 gene-editing technology has dramatically changed the 
way we can model and treat human disease in vivo. In order to test 
the capability of the CRISPR/Cas9 system to correct disease-causing 
mutations, in vivo genetically modified animals can be used. In 2013, 
Wu et al. reported that a mouse model with a dominant cataract-
causing mutation in the Crygc gene could be corrected by co-in-
jecting Cas9 and a sgRNA targeting the mutant allele into zygotes. 
CRISPR/Cas9 system was able to correct the mutant allele via HDR 
pathway using an exogenous oligonucleotide or the endogenous WT 
allele as template and showing very little off-target events.103 This 
was one of the first studies that utilized the CRISPR/Cas9 system 
to efficiently correct a genetic disease. This approach was also used 
in another study that use the mdx mice, a model of Duchenne mus-
cular dystrophy. It is a rare disorder that is inherited in an X-linked 
recessive pattern caused by mutations in the gene that encodes 
for dystrophin, a protein essential for muscle fibre integrity. DMD 
is characterized by rapid and progressive muscle weakness and a 
shortened lifespan, and there is no known cure. Mouse zygotes were 
injected with Cas9 nuclease, sgRNA and a donor template capable 
of correcting the Dmd gene mutation. This experiment resulted in 
genetically mosaic progeny ranging 2%–100% gene correction and 
varying degrees of muscle phenotypic rescue.104
In 2014, another study demonstrated that using the mouse model 
of hereditary tyrosinemia type 1 (HT1), CRISPR/Cas9 system could 
be used to successfully correct a mutation in post-natal animals.105 
They used the Fah59815B mouse model that harbours a homozy-
gous G to A point mutation in the fumarylacetoacetate hydrolase 
(Fah) gene. This modification induces cytotoxic metabolite accumu-
lation and hepatocyte cell death resulting in severe liver damage. 
The authors performed hydrodynamic tail vein injection to deliver 
Cas9 nuclease and a specific sgRNA, along with a single-stranded 
DNA (ssDNA) oligo, used as a donor template harbouring the wild-
type G nucleotide for HDR repair, directly into the mouse liver.105 
Deep sequencing analysis of these animals detected correction of 
the Fah allele mutation which resulted in protein stabilization, lead-
ing to significantly less liver damage. It is important to note that not 
all hepatocytes have been targeted and corrected. Nonetheless, suc-
cessfully edited cells were able to survive, expand and repopulate 
the liver. Hence, disorders where positive selection of edited cells 
takes place are good candidates for successful gene-editing therapy.
Since then, other studies have shown that CRISPR/Cas9 
gene-editing technology could be used for the in vivo treatment 
of other genetic disorders in adult mice. For example, three inde-
pendent groups have used adeno-associated virus (AAV) to deliver 
CRISPR/Cas9 machinery to the mdx mouse model of Duchenne 
muscular dystrophy with the goal of restoring dystrophin expression 
in skeletal and cardiac muscle cells.106-108 This CRISPR/Cas9 method 
mediated by AAV was able to rescue muscle structure and enhance 
muscle function in these mice.
Collectively, these in vivo studies set groundbreaking work in the 
development of new therapies for genetic diseases. For the most 
part, human genetic disorders are uncurable and this is reflected on 
patient's poor life quality and shortened life expectancy. The sig-
nificant progress made in the CRISPR/Cas9 technology enables the 
development of promising treatments and highlights the potential of 
this gene therapy approach to cure human genetic diseases.1
3.2.3 | Application of the CRISPR/Cas9 system in 
cardiovascular disease
Cardiovascular diseases (CVDs) are the number one cause of death 
worldwide according to the World Health Organization. The ad-
vances in CRISPR/Cas9 technology have shown to greatly impact 
the development of new in vivo tools that allow a better under-
standing of mechanisms underlying CVDs. More importantly, the 
expansion of CRISPR/Cas9 techniques accelerated the develop-
ment of novel therapies capable of treating CVDs.109 Accordingly, 
the number of published studies reporting on CRISPR/Cas9 appli-
cations to the field of CVD has increased significantly during the 
recent years. As discussed in the previous section, DMD has proven 
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to be a model disease where CRISPR/Cas9 technology clearly has 
been shown to be successful. Likewise, other heritable cardiomyo-
pathies are promising candidates for genome-editing therapies. Ma 
et al. 110 described for the first time the use of CRISPR/Cas9 to ef-
fectively correct a disease-causing mutation in the MYCBPC3 gene 
in human embryos. MYCBPC3 mutations are the pre-eminent cause 
of hypertrophic cardiomyopathy (HCM), a common inherited disor-
der that results in the abnormal thickening of the left ventricular 
wall.111 The authors found that co-injecting Cas9 with sperm into 
M-phase oocytes resulted in 72.4% of embryos showing a homozy-
gous wild-type genotype.110 Another group was able to extend 
survival and improve cardiac function after ablating the PLN gene 
using CRISPR/Cas9 in a transgenic mice overexpressing a model of 
severe heart failure.112
The availability of viable and efficient delivery methods rep-
resents one of the biggest challenges of translating the CRISPR/
Cas9 into the clinic, as it will be discussed in more detail in the fol-
lowing section. Finn et al. 113 reported the development of a lipid 
nanoparticle system capable of genetically editing the transthyretin 
(Ttr) gene in the mouse liver with a single administration. The authors 
combined the nanoparticle system with CRISPR/Cas9 components 
to target the Ttr gene and observed a significant reduction in serum 
protein levels that persisted for at least 12 months. It will be inter-
esting to test whether this approach will be effective and durable in 
other disease models other than cardiac amyloidosis.
3.2.4 | Application of the CRISPR/Cas9 system in ex 
vivo gene therapy
The success of ex vivo gene therapy relies on the establishment of 
optimized protocols for culturing patient-derived primary cells that 
after genome editing can be transplanted back into the patient. The 
hematopoietic system is an excellent target for this approach, be-
cause target cells can be easily withdrawn from the patient peripheral 
blood and can be re-injected after editing and expansion.60 Clinical 
trials using ZFs as a tool for ex vivo gene therapy are being con-
ducted on patients with several blood disorders, including severe-
combined immunodeficiency, Fanconi anaemia, Wiskott-Aldrich 
syndrome and sickle-cell anaemia.114,115 Recently, a clinical trial has 
shown that gene editing can be used in humans to test and treat HIV 
safe and effectively.116 In this study, ZFs were used to disrupt the 
C-C motif chemokine receptor 5 (CCR5), the major co-receptor used 
by HIV strains to infect T cells. The infusion of autologous T cells ge-
netically edited at the CCR5 locus resulted in the partial induction of 
acquired genetic resistance to HIV infection.116 This approach is now 
being tested in phase 1/2 clinical trials. However, genetically ma-
nipulated T cells do not self-renew and so this treatment could only 
be effective for a specific period of time. The disruption of CCR5 
in human self-renewing hematopoietic stem cells (HSC) as shown 
by Holt et al. 117 using ZFs could potentially solve this limitation. A 
more recent study used the CRISPR/Cas9 gene-editing technology 
to target the CCR5 gene in human CD34+ hematopoietic stem and 
progenitor stem cells (HSPCs). HSPCs that were successfully edited 
via CRISPR/Cas9 technology maintained multi-lineage potential.118 
Another important example of ex vivo CRISPR/Cas9 application is 
the CAR T cell–mediated immunotherapy discussed in more detail in 
the ‘cancer biology’ section above.
The precise selection of genetically modified cells harbouring 
the correct edited allele without undesirable off-target mutations 
represents one of the most important aspects of ex vivo gene 
therapy. As the process of selection is very efficient, and only se-
lected cells will be transferred back into the patient, the accuracy of 
CRISPR/Cas9 is less critical in ex vivo than in in vivo gene therapy.119 
However, one of the major downsides of ex vivo approaches is that 
additional genomic alterations can occur during the required cell ex-
pansion step in culture. This is of pivotal importance, as the cells 
used for the gene-editing step are normally stem/progenitor cells 
susceptible to accumulate mutations and copy number variations 
during reprogramming and expansion. Accordingly, it will be import-
ant to develop assays to measure the integrity and normal function-
ing of genetically modified stem/progenitor cells before advancing 
a therapy to the clinics. Nevertheless, despite these challenges, the 
CRISPR/Cas9 genome-editing tool shows enormous potential for 
bringing ex vivo gene therapy into the clinic in a near future.
3.2.5 | CRISPR/Cas9-mediated genome-
editing applications in translational medicine: the 
challenges and the future
CRISPR/Cas9 system is undoubtedly the most revolutionary tech-
nology in medicine over the past decades. Since researchers were 
able to demonstrate that CRISPR/Cas9 could be repurposed as an 
editing tool, this technology has developed with enormous scientific, 
medical and industry impact. In this review, we have covered several 
examples of how CRISPR/Cas9 technology had direct or indirect im-
pact in the clinic. Despite recent and important advances, several 
issues have to be addressed in order to bring CRISPR/Cas9 genome-
editing tools into the clinic. One of the major obstacles for the 
translation of CRISPR/Cas9 into clinically useful tools is the possible 
off-target effects. Several studies using a variety of approaches, in-
cluding computational predictions, in vitro and in vivo high-through-
put profiling and whole-genome sequencing methods, have reported 
significant rates of off-target effects associated with CRISPR/Cas9. 
It is important to note that unwanted effects of CRISPR/Cas9 such 
as off-target editing and off-target binding might result in malignant 
transformation and other unforeseeable consequences.120-129
The development of methods that minimize off-target effects 
of CRISPR/Cas9 approaches has been a major focus of research. 
One of these strategies requires that two separate Cas9 binding 
events simultaneously occur at the same locus in order to execute 
cleavage of DNA. The inactivation of either of the two catalytic res-
idues within Cas9 converts the enzyme into a nickase (Cas9n) which 
cleaves or ‘nicks’ a single DNA strand instead of a double strand.1,130 
By generating two distinct sgRNAs, DSBs only take place with 
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simultaneous binding events because separate Cas9ns nick oppo-
site DNA strands. As the probability of two off-target sites being 
adjacent in the genome is low, this strategy increases the stringency 
significantly.130 Alternatively, the dimerizing FokI nuclease domain 
which is part of the genome-editing tools ZFS and TALLENs can be 
fused to a nuclease-deficient dCas9 and thereby induce DSBs exclu-
sively upon paired binding.131-133 A recent strategy to limit off-target 
events is based on sgRNA or protein engineering increasing specific-
ity.134-137 Enhanced nuclease Cas9 (eSpCas9) and SpCas9-HF1 are 
two examples of Cas9 variations that have been modified for that 
effect.135,137 A different strategy that reduces off-target events and 
enhances Cas9 specificity relies on reducing Cas9 lifetime or activity 
in cells after time modifying the target locus. For example, the use of 
tightly titrated amounts of Cas9-sgRNA ribonucleotide protein com-
plexes (RNPs), known to be rapidly degraded, can improve the ratio 
between on-target and off-target genome editing in mammalian 
cells, dramatically.1,41,138 Recently, a paper was published describ-
ing an improved Cas9 version named xCas9 capable of recognizing a 
wide range of PAM sequences including GAA, GAT and NG.139 This 
novel variant overcomes an important limitation associated with 
the CRISPR/Cas9 system, the requirement of a PAM sequence at 
the target site. In 2016, Abudayyeh et al. 140 characterized a novel 
type of nuclease, the Cas13a, and showed its RNA-guided ribonu-
clease function. A single CRISPR RNA guides this nuclease that can 
cleave single-stranded RNA targets within bacteria and mamma-
lian cells.140,141 The class 2 CRISPR-Cas family is very diverse com-
prising three distinct types (II, V and VI). Until now, there are four 
known subtypes that belong to type VI, Cas13a, Cas13b, Cas13c and 
Cas13d.28,140-142 Cas13d shows robust knock-down across many en-
dogenous transcripts, and since is one of the smallest Cas proteins, 
it can fit within the packaging limits of a AAV for in vivo delivery.142 
More interestingly, Cas13 nuclease has non-specific RNAse activity 
highlighting its potential as a diagnostics tool.143,144 Besides cutting 
the target DNA or RNA, this family of nucleases is able to cleave 
surrounding single-stranded RNAs (ssRNA). This unique property fa-
cilitated the development of diagnostic kits by using ssRNA reporter 
molecules that fluoresce upon Cas nuclease activity towards a spe-
cific disease-guided RNA.
Another major obstacle for the clinical translation of CRISPR/
Cas9 is the limited efficiency of HDR-mediated gene correction. 
Factors known to determine this efficiency include cell type, cell 
state and competition with the NHEJ. As many treatments of 
human genetic diseases are based on HDR-mediated gene correc-
tion, in which a template sequence is delivered to replace the mu-
tated version, major progress in the efficiency of HDR is necessary. 
Several efforts have been made to increase HDR efficacy, including 
the rational design of single-stranded DNA donors.145 Importantly, 
the design of the sgRNA is also critical to ensure complementar-
ity to the target sequence and minimize off-target cleavage. It has 
been described that mismatches at the proximal 5’ region, relative 
to the PAM sequence, are better tolerated than those at the 3’ re-
gion.146 Therefore, design of sgRNA should avoid mismatches fur-
ther away from the PAM as it increases the probability of off-target 
events. Another strategy is inhibiting the NHEJ pathway147,148 
or increasing the similarity of the donor template and the dou-
ble-stranded break sites.149 ‘Base editing’ is a recent method of ge-
nome engineering that facilitates direct, irreversible conversion of 
a specific target DNA base into another through RNA-programmed 
mechanism, without a dsDNA backbone cleavage or the need of 
a donor template. ‘Base editing’ could represent an alternative to 
HDR-mediated gene correction.150 Fusion of dCas9 to a cytidine 
deaminase enzyme, that acts on single-stranded DNA, allows C to 
U conversion within a window as small as approximately five nu-
cleotides. The fused enzyme is capable of efficiently correcting a 
range of disease-relevant point mutations.150 Another group has 
also developed an adenine base editor that mediates conversion 
of AT to GC in genomic DNA using a tRNA adenosine deaminase 
fused with Cas9.151
Besides its low efficiency, HDR has been considered to be mainly 
limited to applications in dividing cells.152 This fact represents an im-
portant setback for its broad use in the treatment of human genetic 
diseases, making it challenging to apply the technique to post-mitotic 
cells. However, more recently it has been shown that adeno-associ-
ated virus (AAV)–mediated delivery of donor template in combination 
with DNA cleavage by CRISPR/Cas9 allows for precise genome edit-
ing through HDR in post-mitotic neurons in mouse brain.153 Another 
challenge imposed by the need of correcting specific mutations re-
fers to the mutational variability amongst patients with the same dis-
ease. This becomes a big hurdle to overcome when there is the need 
of designing patient-tailored sgRNAs and DNA donor templates. In 
particular, customizing CRISPR/Cas9 gene therapy drugs represents 
a major challenge for effectively scaling production in the future.154
Virtually, all macromolecular therapies have to solve issues of de-
livery that often limit their efficacy.155 Efficient in vivo gene therapy 
using CRISPR/Cas9 will depend on the efficient and tissue-specific 
delivery of its components. The majority of in vivo studies report the 
delivery of therapeutic CRISPR/Cas9 components through viral vec-
tors, especially AAV.156-158 AAV vectors engineered for gene therapy 
seem particularly promising because they can infect both dividing 
and non-dividing cells, they do not integrate into the host genome, 
and they fail to induce a significant host immune response and ef-
ficiently transduce a broad range of cell types.159 However, AAVs 
have a limited packaging capacity for foreign DNA of ≃4.5 kb.160 
Consequently, it is generally not possible packaging all the CRISPR/
Cas9 components, including the Streptococcus pyogenes Cas9 
(spCas9) gene(4.2 Kb), the sgRNA, the donor template as well as as-
sociated promoters and regulatory sequences into AAV.1 Strikingly, 
a recent study used a significantly smaller Cas9 gene (3.2 Kb) from 
Staphylococcus aureus (saCas9) allowing for the integration of a Cas9 
together with a sgRNA into a single AAV.129 Alternatively, the genes 
coding for SpCas9 and its sgRNA can be packaged into separate AAV 
vectors as demonstrated for in vivo CRISPR/Cas9-mediated genome 
editing in mouse brains161 and livers.162
Host immune responses induced by the delivery of bacterial Cas9 
proteins or gene therapy vectors represent another challenge for the 
translation of CRISPR/Cas9 approaches into the clinic. More recently, 
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a mouse model for non-alcoholic steatohepatitis (NASH), a frequent 
liver disease in humans characterized by excessive fat build-up in the 
liver, was generated using spCas9 to delete Pten, a tumour suppres-
sor gene involved in NASH and a repressor of the PI3/AKT pathway. 
Surprisingly, this study describes the production of Cas9-specific anti-
bodies and the secretion of IL-2 from splenocytes that had been engi-
neered with Cas9 system targeting the Pten locus.163 In this study, the 
Cas9 was delivered by adenoviral vectors, known to trigger an immune 
response and might have enhanced that outcome.164 A promising way 
to avoid the immunogenicity of viral vectors is the use of non-viral 
vectors including nanoparticle- and lipid-based vectors.165,166 A possi-
ble strategy to limit the immunogenicity of Cas9 peptides is humaniz-
ing the Cas9 protein.154 Accordingly, finding methods that reduce the 
immunogenicity of the in vivo CRISPR/Cas9-mediated gene editing 
will be an important focus of upcoming researches.
3.3 | Ethical concerns
The burst of CRISPR/Cas9 applications also highlighted the potential 
of this system and the ethical concerns associated with the possible 
creation of permanent and inheritable changes in the human ge-
nome. Having in mind the ethical implications, legal action was taken 
to delay germline genome editing. The first report using CRISPR in 
human embryos was back in 2015 where Liang et al. 167 performed 
experiments in discarded embryos with an extra pair of chromo-
somes. Nonetheless, gene correction efficiency was very low and the 
successful ones showed genetic mosaicism with a low percentage of 
cells being accurately edited. Another group reported that they had 
successfully edited three out of six viable human embryos.168 They 
have used immature oocytes that had to go through in vitro matura-
tion. More recently, Ma et al. 110 utilized CRISPR in human diploid 
zygotes to correct a mutation causative of hypertrophic cardiomyo-
pathy, a congenital heart disease, claiming high-efficiency and few 
side effects. The group of Dr Huang at ShangaiTech University used 
a new CRISPR method, the recently developed base editing (dis-
cussed in the previous section) to correct a single base in the FBN1 
gene involved in the Marfan syndrome, a rare autosomal dominant 
disorder in heterozygous embryos.169 The embryos were obtained 
by injecting sperm from a patient with Marfan syndrome into a ma-
ture oocyte. The authors showed that 89% of the embryos were ef-
ficiently edited, and more importantly, no off-target and indels were 
detected. It is evident that we are on an accelerated pace towards 
using CRISPR genomic engineering as a biomedical therapy. But is 
also urgent that discussions about ethical guidelines within interna-
tional multidisciplinary groups take place to regulate and minimize 
the potential risks associated with this powerful tool.
4  | CONCLUSIONS
The CRISPR/Cas9 RNA-guided DNA endonuclease system is a ver-
satile technology that has rapidly transformed genome editing and 
basic science research. The development of improved CRISPR/
Cas9 tools with high degree of DNA specificity, increased selectiv-
ity and low level of by-products made this technology accessible to 
researchers worldwide to study human diseases. For example, it is 
now feasible to generate in vivo animal models of specific diseases in 
a few weeks. It is now possible to envision the treatment of genetic 
diseases in the near future using this technology. In fact, several clin-
ical trials using CRISPR/Cas9 approach to treat human genetic dis-
eases are underway (NCT03872479 or NCT03399448). However, 
we still need to improve the efficiency, specificity and delivery of 
this technology for its broader application in the clinics. A major 
concern that accompanies the use of CRISPR/Cas9 in the clinical 
setting relates to the potential risk of misusing this technology. The 
development of ethical and regulatory guidelines is critical to ensure 
that the benefits outweigh and minimize the risks. The discovery of 
CRISPR/Cas9 technology and its application in the clinics is a true 
example of the importance of bridging basic research and transla-
tional medicine. Once the CRISPR/Cas9 mechanism was unveiled, 
the possibilities of medical exploitation were enormous and will defi-
nitely change the way we will treat genetic disorders in the future.
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